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Abstract
The United States correctional system is a vital treatment source for chronic illnesses. Whether treating a
chronic mental or physical illness, correctional healthcare requires effective resource utilization. Limited
research exists on pharmacists' ability to directly address inmate medication adherence. Thus, this study
explores inmate perception of medication adherence and management as part of their treatment plan. Semi-
structured interviews were conducted with inmates throughout Connecticut. Diseases of interest were
divided into a physical illness group (hypertension, diabetes mellitus, HIV/AIDS) and a mental illness group
(depression, bipolar disorder, schizophrenia, substance abuse). A content analysis was conducted on four
questions: 1) Do you take your medications as prescribed, and why? 2) How do you feel about taking
medication for your illness? 3) Are you experiencing any problems or side effects due to your medications and
how do you handle this? and 4) Have there been any changes to your medications and how was this process
handled?
Interviews were conducted between January and December 2015 with 23 male inmates (n= 7 in prison; n=16
in halfway houses). A total of 6 inmates reported non-adherence, 17 reported adherence, 7 had a physical
illness, and 16 had a mental illness. A total of 16 themes were identified through the four questions.
Overall, the pharmacist's medication knowledge and availability allow for medication management and
support of inmate medication adherence. Inpatient, pharmacists are suited to perform comprehensive
medication therapy management for the psychiatric population and other chronic illnesses. Outpatient, the
community pharmacist is poised to supply medication information and guidance to transitioning inmates.
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Introduction 
The purpose of this study is to investigate the way pharmacists can serve 
incarcerated and newly released prison populations by addressing medication 
adherence and managing medication therapy. Interviews were conducted to gauge 
inmates’ opinions of their medication regimen, experience with the health care 
system, and ultimately identify factors most important for effective medication 
therapy management. Feedback gained from these interviews will help define 
how the pharmacist, whose clinical responsibilities have expanded, can better 
support medication adherence among incarcerated individuals. The data for this 
paper comes from a cross-sectional parent study entitled “Interviews with Inmates 
on Self Care Needs”, also known as “Inmate Self Care”. This study examines a 
subset of interview data from the parent study answering the question: How do 
correctional patients perceive medication adherence and medication management 
as a part of their treatment plan?              
Background 
Health care in the United States (US) is moving towards a value-based care model 
where health resources are being strategically used to achieve the “Triple Aim” of 
lower health care costs, improving population health, and improved patient 
experience1. Major goals of this movement include care coordination and 
addressing both the tangible and intangible aspects of health care1. Highly 
important to this movement is patient medication adherence, defined here as the 
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extent that patients take medications as prescribed by their health care providers2. 
When put into practice, medication adherence has the potential to drive significant 
savings for health systems by controlling chronic conditions, preventing hospital 
readmissions, and decreasing morbidity3. The system-wide cost of drug-related 
problems such as non-adherence was shown in a 2008 study conducted by the 
New England Healthcare Institute to be over $290 billion- a total that has likely 
increased due to inflation4. Recent data shows about 49% of Americans take at 
least one medication and between 35-50% are non-adherent5. If prescribed 
medications are neglected, patients generally do not achieve targeted health 
outcomes and may see a worsening of their condition. As well, non-adherence can 
put patients at higher risk for mortality and the associated costs of intensive 
inpatient services when admitted to the hospital, with over 10% of 
hospitalizations attributed to lack of medication adherence3,6. With that, 
addressing medication adherence can bring about a multitude of benefits and fits 
into health care’s new culture of improved patient outcomes through increased 
care quality.   
 The US prison population represents a diverse body of individuals with a wide 
array of chronic illnesses. As of 2014, over 2.2 million individuals are currently 
sentenced in a Federal prison, State prison, or local jail at a rate of 900 
incarcerations per 100,000 US residents- one of the highest rates in the world7. 
Among the correctional population, there is a high incidence of mental health 
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illness, with a Department of Justice study estimating that 45% of Federal, 56% of 
state, and 64% of local jail inmates suffered from at least one mental illness8. 
These conditions include bipolar disorder, schizophrenia, depression, and others 
that often go undiagnosed during the inmates’ life. The same report showed that 
74% of state and 76% of federal prisoners with mental illness, respectively, were 
also likely to exhibit substance abuse8. Aside from those with a mental illness, the 
incarcerated population exhibits diseases comparable to the free world such as 
hypertension, diabetes, and HIV9. A recent study estimated that 40% of inmates 
have a chronic illness of a physical nature, irrespective of mental illness10. In 
practice, correctional health care occurs in a highly coordinated and regimented 
environment when compared to the free world. Although inmates are regulated 
and under intense scrutiny, non-adherence continues to exist because, like in the 
free world, inmates can choose to neglect their treatment or refuse prescribed 
medication regimens.  
Progressing through the correctional system, inmates in need of treatment, 
often referred to as inmate-patients, face a diverse set of health care-related 
obstacles. Periods of transition are especially challenging for maintaining 
adherence as inmate-patients face relocation, insurance change, and complete 
reestablishment of their medical care team. With over 600,000 prisoners released 
to the community in the US on an annual basis, the challenge is widespread and 
readily apparent11. On release, inmate-patients must relearn the community-based 
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system they once participated in, while adapting to changes that have been made 
since the Affordable Care Act (ACA) in 2010. When transitioning at the end of a 
sentence, inmates will be directly released to the community, while others, 
released under transitional supervision, will exit prison in a stepwise-approach 
and spend time in a halfway house12. On departure from correctional health care, 
to either the community or a halfway house, an inmate must assume full 
responsibility for their health care and will often depart with a short supply of 
medication13, or voucher. In either case, those on chronic medication therapy will 
eventually need to refill their medications and it is then that the inmate will 
encounter an important community health care provider; the pharmacist.  
 For inmates and the community as a whole, the pharmacist presents as a 
viable resource for promoting medication adherence and managing medication 
therapy. When considering access to health care, the pharmacist is viewed as the 
most accessible health care professional and consistently ranks in the top most 
trustworthy professionals14,15. With over 110,000 total pharmacists employed by 
chain retailers and independent pharmacies in the US, the public can’t go far 
without encountering a pharmacist16. The services of the pharmacist are unique in 
that there are few other instances in the US health care system where an 
appointment is not required to receive free professional input. A pharmacist’s 
education includes extensive training on side effect monitoring, preventing drug 
interactions, and optimizing both the safety and efficacy of medication regimens; 
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making them well-equipped to resolve adherence discrepancies17. In addition to 
pharmacotherapy management, pharmacists receive communication training to 
better elicit information from patients and motivate change in those that want to 
alter their habits in a positive way17. Recognition of pharmacists’ capabilities is 
becoming apparent as professional organizations increasingly call for their 
involvement in addressing unmet public health needs, drawing the profession 
further into patient care.  
At the national level, professional organizations such as APhA are lobbying 
for attainment of pharmacist provider status in rural and underserved areas18. 
Pharmacists already receive compensation from the federal government through 
Medicare Part D for Medication Therapy Management (MTM), a comprehensive 
medication review aimed at increasing safety and efficacy of medication 
regimens, but federal provider status recognition would allow for expanded 
clinical scope19. The components of MTM have been standardized through input 
from several professional organizations and have been formally compiled as a 
resource called the “Patient Care Process”20. Here the pharmacist conducts MTM 
with the patient’s preferences and outcomes at the center of their service. Aside 
from the federal movement, Collaborative Drug Therapy Agreements (CDTA) at 
the state level give pharmacists prescriptive responsibility for specific disease-
states or specific populations of patients21. Here, pharmacists play a greater role in 
therapy management as an extension of the traditional physician-patient 
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relationship. Recently, the American Society of Health-System Pharmacists 
(ASHP) released the first guidelines on pharmacists’ role in correctional health 
facilities, advocating that facilities obtain the services of pharmacists to ensure 
safe and effective care; a sign of pharmacists’ evolving role and ability to impact 
care in diverse settings22. 
Availability, knowledge, and expanding services make the pharmacist 
ideal for medication therapy management and promotion of medication adherence 
for all participants in the health care system. Inmate-patients, who represent a 
vulnerable population with limited resources and a high comorbidity burden, may 
benefit from pharmacists’ services and ultimately experience improved health 
outcomes. Thus, this study seeks to explore factors affecting inmate medication 
adherence that may be influenced by pharmacist intervention. Justification for the 
present study stems from the structural care processes and patient needs that are 
inherent to the correctional health setting. By conducting exploratory interviews 
with inmate-patients, opportunities for pharmacist intervention will be defined 
and additional hypotheses concerning medication adherence will be generated. 
These opportunities will ideally target the root cause of non-adherence and guide 
future work to support adherence to obtain positive health outcomes. With the 
efforts brought on by the ACA to facilitate inmate participation in healthcare and 
support from many professional organizations, the progressing role of the 
pharmacist can be further refined to address inmate-patients' health needs. 
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Methods 
Parent Study  
The data for this analysis comes from an ongoing parent study called the “Inmate 
Self Care” study that began in 2014. The purpose of “Inmate Self Care” is to 
explore the factors affecting inmate-patients’ ability to perform self-care in a 
correctional setting. The study’s ultimate goal is to develop a solution, in the form 
of a patient-centered tool or policy recommendation, to improve inmate-patients’ 
self-care habits and allow them to receive the greatest benefits from care. “Inmate 
Self Care” also served as an internship opportunity for pharmacy students to 
participate in data collection and data analysis for an interprofessional research 
project. 
Contractual authorization for the study was obtained from the Connecticut 
Department of Corrections (CDOC) and a Certificate of Confidentiality (# MH-
14-63A) was obtained from the National Institutes of Health (NIH). Study 
participants were recruited from two Connecticut Correctional Institutes and eight 
work-release or inpatient halfway houses.   
Planned enrollment for the parent study was 140 participants with the 
following characteristics: male, female, adherent, non-adherent, diabetes mellitus, 
HIV/AIDS, hypertension, depression, bipolar disorder, schizophrenia, and 
substance abuse. The planned enrollment is further outlined in Appendix- Table 1.  
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Semi-structured interviews were utilized to explore inmate- patients' 
perspectives on adherence to medication and medication management in a 
correctional setting. Thirty questions were developed as an exploratory core for 
the parent study based on previously identified psychosocial and pharmacologic 
factors affecting treatment adherence23–25. Efforts were made to probe interview 
participants in order to provide further insight into interview questions. 
Demographic information was collected including date of birth, gender, ethnicity, 
education level, work history, family support, and current chronic medical 
conditions. Completion of all interview questions was expected to take 30-45 
minutes based on applicability to each participant and depth of response.  
Adherence status would be assigned after review of the participant’s 
medication administration record (MAR) for the previous three months. If the 
patient took 80% or more of their prescribed doses, they were considered 
adherent; non-adherent if they did not meet this threshold26,27. If the MAR could 
not be obtained, adherence would be assigned based on participant self-reporting. 
Sub - study Design 
Following the same projected enrollment as the parent study, this study sought to 
answer the following question: How do correctional patients perceive medication 
adherence and medication management as a part of their treatment plan? 
Assessing this question has important implications for pharmacy practice because 
it offers insight into inmate-patients’ day-to-day health care experience 
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throughout the correctional process. Such insight will help define opportunities 
for pharmacist intervention, allowing for optimal use of resources and attainment 
of beneficial health outcomes.   
To address this, four questions were selected for primary analysis from the 30 
parent study questions: 
Question 1 (Q1)- Do you take your medications as prescribed, and why? 
Question 2 (Q2)- How do you feel about taking medication for your illness? 
Question 3 (Q3)- Are you experiencing any problems or side effects due to 
your medications and how do you handle this? 
Question 4 (Q4)- Have there been any changes to your medications and how 
was this process handled? 
These questions were selected specifically for their focus on medication 
adherence and management. The former is addressed by both Q1 and Q2, which 
serve to elicit more information about the inmate’s overall adherence and 
perception of medication. The latter, addressed by Q3 and Q4, targets inmates’ 
experience with medication changes and their interactions with providers through 
the management process. 
Sample 
For inclusion in the study, participants were required to be over the age of 18, 
currently prescribed a treatment for a chronic illness, English speaking, and have 
an incarceration history of at least 6 months. Chronic illnesses of interest 
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included: depression, bipolar disorder, schizophrenia, substance abuse, 
hypertension, diabetes mellitus, and HIV/AIDS. The participant’s primary 
diagnosis with active treatment determined categorization into either a physical 
illness group consisting of hypertension, diabetes mellitus, and HIV/AIDs; or a 
mental illness group consisting of depression, bipolar disorder, schizophrenia, and 
substance abuse. These diseases were chosen because they are frequently 
occurring in the general population, can be maintained with appropriate 
medication regimens, and generate significant costs when the diseases are 
uncontrolled. Adherence status was determined based on inmates’ self-reported 
medication adherence for the previous 3 months.  
Study Recruitment 
Participants for the sub - study were recruited from one Connecticut Correctional 
Institute and four work-release or inpatient halfway houses.  Recruitment 
procedures included use of posted fliers advertising the study which were hung in 
each facility through coordination with CDOC personnel. Each flier noted criteria 
for study enrollment with instructions to place a note in the sick call box if 
interested. Recruitment periods covered two weeks, at the end of which a date 
was coordinated with the CDOC staff to interview all interested inmates. The 
purpose, procedures, minimal risk, and potential lack of direct benefits of 
participating in the study were discussed on first meeting participants. Informed 
consent was then obtained, with participants acknowledging that they had the 
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right to refuse audio recording, could refuse disclosing their medication 
administration record, could abstain from answering any question, and could 
leave the interview at any time with the interview materials being subsequently 
destroyed. Signed informed consent forms were retained and stored separately 
from subsequent interview documentation to maintain de-identification. 
Interview Procedures 
On the determined interview date, researchers met with inmates in the general 
visitation room or private consultation rooms. At the start of the interview, 
inmates were provided full details of the study, informed of the NIH Certificate of 
Confidentiality, and written informed consent was obtained.  Interviews followed 
a semi-structured format, were audio recorded, and handwritten notes were taken. 
In addition to the interview questions, demographic information was obtained 
from each participant including their medical conditions and current medication 
regimen. Each interview was de-identified through the replacement of the 
inmate’s name with a number starting with 01. Audio recordings were later stored 
on an encrypted computer to maintain security. Individual interview notes were 
stored in a double-lock system, e.g. in a locked cabinet within a locked room at 
the University of Connecticut.  
Analysis 
Each interview was transcribed by a member of the research team and was 
subsequently reviewed by a different team member. During transcription, a 
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concerted effort was made to highlight the inmate’s phrasing of certain answers, 
points of emphasis, and any other verbal cues that could elude their emotional 
stance on the topic. To ensure accuracy, 20% of interviews were validated 
through performing a second transcription by another team member and were 
cross-checked with all supporting notes. The interview transcripts, procedures, 
and analysis were reviewed by a veteran nursing professor to further ensure 
accuracy.  
Content analysis began with a focused review of all transcripts by the research 
team with all analysis performed using NVivo 11 Pro (version 11, QSR 
International). The analysis was guided by previously identified psychosocial and 
pharmacologic factors affecting medication adherence23–25. After an initial review 
of all interview transcripts, responses to each question were interpreted and their 
underlying context served as themes. These themes were coded as nodes in 
NVivo and a node hierarchy was continually refined throughout the analysis. 
After coding all transcripts, each node was reviewed to determine if saturation 
was reached. After saturation was reached, themes were finalized for each 
question, and representative quotes were identified. 
Results 
Sub - study Sample 
All sub - study interviews were conducted between January and December 2015, 
each averaging 30 minutes in length. The sub - study sample included 23 male 
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inmates located in one prison and four halfway-houses throughout Connecticut 
(Appendix- Table 2). 
Content Analysis 
In total, 6 inmates were non-adherent, 17 were adherent, 7 had a physical illness, 
and 16 had a mental illness. For the physical illness group, 1 was non-adherent 
and 6 were adherent. Among the mental illness group, 5 were non-adherent and 
11 were adherent. All inmate-patients that consented to participating in the study 
fully-completed their interviews and there were no study dropouts. The 4 selected 
questions, out of 30 original study question, were coded with NVivo 11 Pro and 
their respective themes are presented on a question-by-question basis. Quotes are 
provided from the respective study participants. Overall 16 different themes were 
identified and reached saturation (Appendix- Figure 1). These themes could then 
be further classified as promoting adherence, non-adherence, or impacting 
medication management (Appendix- Table 3). 
Q1. Do you take your medication as prescribed, and why? 
In gauging patient’s perceptions of medications, it was first necessary to 
determine whether or not patients were taking their medications and why. Themes 
identified for Q1 included: Momentary Disruptions, Timeliness, Lack of Need, 
Personal Beliefs, and Patient Education. 
Momentary Disruptions 
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Most of the instances of non-adherence could be considered temporary in nature 
and resulted from momentary disruptions to an inmate's normal habits. As 
expected, it was rare that inmates reported simply forgetting as a reason for non-
adherence. Several of the reasons for non-adherence related to procedures 
associated with medication administration. One inmate described not taking his 
medications because the nurse was not using gloves, making the medications 
unsanitary: 
“I don’t like the way some nurses here give out medication. Like the other 
day, I was going to refuse my meds…The nurse started dumping my 
pills…A couple of the pills fell out onto the counter and she did not have 
any gloves and she felt it was alright to scoop up the pills with her bare 
hands back into the cup and hand me the cup. This got me mad because 
you are not going to go to a restaurant and let a waitress or waiter grab 
your food or play with your food with their bare hands. This is something 
that is going into my mouth and my body.” (02) 
 
In one case the prison’s evening medication call conflicted with the television 
show American Idol, and thus his medications went untaken: 
 “P:...I missed it because they called us out at around 8:30 to get our meds 
and I was watching American Idol and did not want to miss it. 
I: Was that for all the medications? 
P: Yeah for all of them. I am pretty sure.” (02) 
 
Timeliness 
The amount of time required to obtain their medication was also a factor driving 
non-adherence. In dealing with the medication line, it was stated that the nurses 
take too long, causing the inmate to become frustrated with waiting and then exit 
the medication line before receiving their dose:  
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“Um, the nurse that we have is just too slow. And I’m not part of standing 
in line and waiting forever. I said you know what, I told the CO, mark me 
as a refusal. I refuse everything.” (01) 
 
In acute instances where over-the-counter (OTC) medications were needed, such 
as joint pain or relief from a common cold, inmates could obtain necessary 
medication from the commissary. Here, OTC products could be purchased 
through an inmate’s bank account, providing expedited relief compared to the 
health system at a comparable price: 
 
“Patient (P): …they (the nurse) would find out our symptoms and write 
them down in our file to be referred to a doctor.  
Interviewer (I): Would they ever turn you away and say go to 
commissary?  
P: Umm they always just tell us to go if you got money on the books 
‘cause it costs you 3 dollars anyway. To see the doctor is another 2-3 
weeks.  
I: Did you find yourself buying a lot of OTC products off the commissary?  
P: I did everything. Antihistamines, Tylenol.” (19) 
 
Lack of Need 
Inmates often expressed periods where they were sufficiently maintained on 
therapy and had a perceived lack of need for their medications. An instance of this 
occurred during a “reality check”, where the patient wanted to check the status of 
their condition without medication:  
 
“I just wanted to feel again, I just wanted to see how good I was really 
doing. And it was just like a reality check.” (09) 
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Here, another inmate described “highs” that caused him to see no need for 
medications. After stockpiling skipped doses, their mental condition would 
decline and they would eventually overdose on the accumulated medication: 
 
“Yeah it’s just I’m just in one of my moods, you know, I’m on one of my 
highs you know where I’ve been doing really good for a while and I’m 
like “you know what today I don’t need it, tomorrow I’ll take it. I’ll do the 
cheat method where I just put it underneath my cheek or underneath 
my…I’ll stack them in my cell like I took them for a couple of days and 
then because I haven’t been on them for a while my depression comes 
back and now I get depressed, now I have thoughts of hurting myself, so I 
immediately get attention. I’ll be like “Oh yeah you want to do that? Well 
watch this, see these pills?” And the guy will call the court and I’m getting 
all the attention. Then I’m on the meds, I’m doing what I’m supposed to 
be doing. And then I’m like I’m doing so well I don’t need the meds 
anymore, and then I slide back down and crash for a while and then I get 
back on them. (01) 
 
Personal Beliefs 
At times, inmates presented with a strong belief, most often unfounded, that 
influenced their adherence. Here a patient reported not taking his medication over 
fear of drug tests resulting in a false positive:  
 “I’m trying not to take a lot of it because I was told it could make a false 
positive…that’s why I stopped taking everything cuz I want to make sure 
that my tests are clean.” (11) 
 
One inmate with a mental illness mentioned a general embarrassment from taking 
psychiatric medications, but noted the benefits gained from treatment. In this way, 
the negative impact of public opinion was present and acknowledged, but the 
inmate continued to actively participate in treatment: 
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“I am more embarrassed by it. Ashamed I guess you could say. I am not a 
control freak but I like to be in control of myself, which I am sure 
everyone does. We are adults not children. I do not like the fact I have to 
use chemicals to stay in control of myself, but I guess that is something 
personal I have to get over.” (02) 
 
Patient Education 
The beneficial effects of patient education were seen through adherence, as one 
inmate described how his doctor helped establish a regimen that best suited his 
needs: 
“…if it’s one thing I will say, and I’ll only give credit to doctor I had 
when I first came in, she was very patient with me, and understanding that 
I didn't want to be all doped up on meds…but the lithium itself, that’s 
really done wonders. It really just stopped the suicidal thoughts from 
happening, like just cold turkey…so I really give the credit to the 
medication and taking them as prescribed.” (03) 
 
Q2. How do you feel about taking medication for your illness? 
After determining adherence, the inmate’s perception of medication’s role in 
therapy was subsequently analyzed. Whether medications were valued or not, 
along with the perceived benefits or risks, and the reasons supporting their 
answers were elicited through this question. Themes identified for Q2 included: 
Tangible Benefits, Potential Risks, Acute Relief, Counseling, Loss of Faith. 
Tangible Benefits 
For those finding value in medications for their condition, the most readily 
apparent theme identified was tangible benefits. Whether a mental or physical 
18 
illness, those supporting medications gave clear examples of the benefits they 
received: 
“Effexor is a miracle drug. I’m happier now… even in the world I had 
problems, suicide and stuff like that, and you know, suicidal thinking, and 
then umm when they put me on Effexor, it just you know kind of evened 
everything else.” (08) 
 
“Well listen, when I’m over 20 years for HIV and I’m never get better but 
never got full blown AIDS, the medication is doing something.” (12) 
 
Potential Risks 
Many others were motivated by the potential risks of an uncontrolled illness such 
as diabetes, an underlying heart condition, or feeling the negative physical effects 
in the absence of medication:   
“Since I have been in I take everything. I am not risking going blind just 
because I do not want to take some pill.” (21) 
 
“I have an issue in that area so imma be on my meds, you know because 
high blood pressure do that to your ticker. And I always had a little heart 
problem, since ’91 they told me I had a little black spot on the back of my 
heart.” (22) 
 
“I'm taking the water pills, I know I can't breathe- you know? And I know 
that pill is doing me good- you know? If I have any problems I make sure 
I take that water pill- you know?” (23) 
 
Acute Relief 
In some cases, the acute benefits mattered most to the patient such as during an 
anxiety attack: 
“…it's like sometimes like every time it pop I need to take ‘em. I don’t 
want to have that, because I see people dying from anxiety, you know? 
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And I don’t want that to happen. Like, last week it was bad. I was like, I 
can't breathe I can't breathe, can you take me to the Doc?” (15) 
 
Counseling 
Another common theme was the benefits of group therapy and the different forms 
of expression it provided patients: 
“And the treatment helps give me outlets, different outlets to take- you 
know? My major outlet was violence, and drinking and drugging. And the 
therapy and the treatment helps me, like there is different avenues- you 
know? Like I said I never wrote poetry in my life, I’m like that’s for saps. 
And I’m like one of the toughest poets now. I sit there and I’m like ughhh 
and then by the time I finish I’m like oh my god, I wrote over two pages!” 
(17) 
 
One inmate acknowledged both the benefits of new medications and counseling 
programs on release from solitary confinement. Here he stated that a change in 
environment and access to groups led to all-encompassing benefits: 
“Um it’s hard for me to tell because I was in solitary confinement for 16 
months in the super max, and again how I got there was because I was on 
medications that weren’t working …I’m not sure if it’s because I have a 
lot more freedom because I’m not locked in a cell 23 hours a day with 
minimal human contact. So, there’s a lot more freedom for me to do 
programs like NA and AA, there was also a dual recovery program for 
people who have mental health problems and addiction. Um, really just 
services, and then we have creative writing and theatre classes. Plus, I’m 
able to have rec twice a day. Soooo- I don’t know if it’s that or the 
medication I’m taking or a combination of both.” (07) 
 
 
Lack of Faith  
Instances where inmates saw little value in their medications were rare, occurring 
in only 4 interviews. In a broader sense, inmates’ non-adherence derived from a 
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greater loss of faith in the health care system and the treatment they received. One 
inmate placed no value in his medication regimen because of being through the 
process so many times and feeling like a “guinea pig”:  
“Yeah um I’m kinda skeptical about medications. Because I’ve been doing 
this for so long I kind of feel almost like a guinea pig. Like there’s no fix it 
pill. Ya know what I mean? Um, I’ve like I said taken so many 
medications over the years.” (07) 
 
Disinterest in medications arose from lapsing refills, where an inmate located in 
the halfway house ran out of their current supply without a follow-up prescription: 
“P: …just recently I ran out of high blood pressure pills. When does the 
doctor anywhere, unless he knows your blood pressure is safe, take you 
off pills and say there is no refills? I’ve been taking these things for like 
10-15 years. 
I: Oh, so you didn’t have any refills? 
P: There's just no refills. What are you out of your friggin mind? Now I'm 
running around here with no pills and high blood pressure and sure enough 
I got pissed at someone the other day and yelled at them and got written 
up.” (18) 
 
Q3. Are you experiencing any problems or side effects due to your 
medications? How do you handle this? 
Side effects often play a major role in medication adherence; thus, it was 
necessary to explore inmates’ experience with medication side effects. In this 
way, their medication management and resulting adherence could be better 
understood. Themes identified for Q3 included: Cognitive Side Effects, Therapy-
limiting Side Effects, Physical Side Effects, and Patient Education. Side effects 
reported were seen with antipsychotics or mood-stabilizing medications causing 
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significant mood changes, drowsiness, weight gain, or extra-pyramidal side 
effects (EPS), or reported by patients with a mental illness. This often-fostered 
disinterest and non-adherence in the medication regimen.  
Cognitive Side Effects 
As mentioned, changes in mood often had an adverse impact on the patient and 
required therapy change: 
“I was on Abilify and I stopped taking that. There was a big issue here 
surrounding me being taken off that medication because it made me feel 
almost frantic. I do not know why or what caused it. I don’t know if it was 
the pills or dosage, but it gave me this feeling that if I did not get 
something done right away that something bad would happen.” (02) 
 
Drowsiness is a common side effect for antipsychotics and can be another source 
of medication discontinuation. Here the side effect was viewed in both a favorable 
and unfavorable light: 
“P: Sleepiness, drowsiness. Trilafon puts me asleep. Not too much, but 
makes me a little drowsy. (pause). Other medications I don’t think there 
are any side effects that really bother me. 
I: Are you annoyed by the drowsiness? 
P: Not really, I don’t have nothing else to do but sleep.” (02) 
 
“What they want is a therapeutic level and you know usually the 
therapeutic level got me where I’m drowsy...you know I feel like I’m not 
myself and you know I don’t like that feeling.” (01) 
 
Therapy-limiting Side Effects 
The presence of EPS, facial twitching and other involuntary movements, is a 
constant concern with antipsychotic medications and is often a treatment limiting 
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factor. Here a patient exhibited signs of EPS which led to a change in their 
therapy: 
“I: Do you have any problems or side effects that you think you can 
attribute to your medications? 
P: yeah - well - tremor in hand…my lip was like moving, involuntarily too 
- but umm, they switched my medication up and the pros and the cons 
outweighed the pros or whatever it’s called.” (08) 
 
Physical Side Effects 
An example that appeared several times was significant weight gain from lithium. 
Patients noted the benefits of lithium but stated that the additional weight was 
impacting their lives. The additional weight gain presented as a common factor 
for patients wanting to change their medications: 
“…I’m trying to get off my lithium because it is bloating me. It’s like, 
making me overweight I think. I’ve gained a lot of weight on the lithium. 
More than I’ve ever had in my life…it was actually dramatic…I ended up 
gaining like 40 pounds in like 4 months.” (05) 
 
Patient Education 
Inmate-patients demonstrated an understanding that doses are titrated for 
optimum effects but complained of negative side effects on dose increases; 
especially with psychiatric medications. These changes were mitigated by care 
providers explaining what was happening and assuring the inmates that this 
experience was only temporary. In this case, the nurse was supportive of the 
patient going through a dose increase: 
“Every time I go through the increase, for a couple days I get real bad 
headaches, my hands start shaking real bad and um, I just don’t like the 
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feeling. So, she kinda worked with me she said ‘okay well what we will do 
is we will keep you at where you are at…if you start acting out again, 
we’re just going to increase your meds and you can refuse them then we’ll 
go from the next step from there but as of right now, you know, you can 
stay at it’.” (01) 
 
Q4. Have there been any changes to your medications? How was this process 
handled? 
Inmate-patient’s medication regimens undergo change for a variety of reasons and 
the processes surrounding these changes vary. The goal with this question was to 
elicit information about the management of inmates’ medication regimens to 
identify practices that influenced adherence. Themes identified for Q4 included: 
Patient Education, Unmatched Expectations, Limited Provider Access, and Data 
Use. 
Patient Education 
When changes were necessary, clinicians took time to explain the therapeutic 
alterations. Inmates reported that they were consistently informed why a 
medication was added or discontinued, or why a dose was changed. In many cases 
the education received from the care provider had a large impact on the patient’s 
participation in treatment:  
“I was really lucky when I first came into the county system, the doctor 
I had, she was, uh very, very nice, very educated, very professional, but 
more than understanding, so from the very start, she addressed my main 
concern which was medication. I didn’t want to take medication, not 
that I didn't believe in it, but first hand I saw what medication um, does 
to some of the patients that I worked with, when they had been 
medicated, and I didn't want to get diabetes, anger issues, violent 
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tempers.” (03) 
 
“Dr. G spent time with you and showed you how important it is to take 
the medication, and if you don’t take it this could happen... if you don’t 
take them correctly or if you don’t mix them up correctly they don’t 
work. Dr. G always used to explain correctly. He cared more for us…he 
explained everything correctly and prescribed me the right medicine 
and so I believe that with him is the reason I’m still here because I 
lasted so long and taught me more about my disease that I have. Dr. G 
taught me that if I skip a day or two the virus can figure out the 
medication and the medication won’t work for me so I always try to 
take it but in the world it’s hard for me." (20) 
 
Unmatched Expectations 
At times medication changes were not always welcome, and opinions of alteration 
to the medication regimen were different between patient and provider. One 
inmate reported his provider wanted to change his medication dose, but he 
resisted due to comfort at the current dose. In this case, a change to the inmate-
patient’s regimen may have caused a moment of instability:  
“I don't really like when people mess with my medication. Cause I’m 
doing well, even though - since I am doing well they say we need to 
start cutting back on your medication. I mean come on, I’m doing well, 
why mess with my medication- you know?” (08) 
 
Limited Provider Access 
Access to care, limited by physical and administrative barriers, played a large role 
in the degree to which medication changes could be made. One inmate, who had 
just arrived in the halfway house, sought to resolve his lithium side effects but 
was unsure how to do so: 
“I: Have you talked to your doctor about that?  
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P: No, I’ve gotta talk to them, I don’t know how. I’ve gotta figure out how 
to go about doing that because you go back into the jail to do that so…” 
(05) 
 
Data Use 
Medication changes were also the result of blood level monitoring, as in this case 
where an inmate’s prolactin levels called for a change to their medication 
regimen:  
“…there was a point in time where they were trying to decrease the 
medication and then I started to get agitated and my mood started to 
change…they stopped giving me Risperdal cause of my prolactin 
levels…and I started getting a sensitive chest…they put me on 
Zyprexa instead of Risperdal.” (08) 
 
While monitoring blood levels for certain medications can lead to appropriate 
therapy selection, one inmate presented what occurs when labs such as viral load 
are neglected: 
“P: …he was the one that took me off my meds back in 2005…I lost my 
weight, I went from 235 down to 167 pounds  
I: Okay what was it he took you off, do you remember, or what it was for?  
P: My HIV  
I: Did he replace it with anything?  
P: No  
I: So how long do you think you were without treatment for your HIV?  
P: At least a few months  
I: And then he started back up again?  
P: Yeah when he saw my numbers but I was telling him all along I had 
problems, so they took my gallbladder...” (22) 
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Discussion 
Thematic Overview 
The 23 inmates interviewed provided perspectives on their experience receiving 
treatment for a chronic illness in the correctional health system to better 
understand the role pharmacists may play in their care. Through the four 
questions, information was successfully obtained about inmates’ perception of 
medication adherence and medication management for their respective illness. 
Most of the study population self-reported adherence to their medication regimen 
(17/23, 73.9%) and the majority interviewed were located in halfway houses 
(16/23, 69.6%). No clear difference was seen in the reported adherence between 
the physical and mental illness groups.  
Responses to all questions from halfway house and prison participants were 
consistent in nature, likely because halfway house residents experienced the same 
care processes in the recent past. When medication changes were reported, they 
almost always occurred with the goal of reducing side effects to make treatment 
bearable for the patient. As well, when changes were warranted, there was no 
dissatisfaction with the therapeutic alternative expressed among interviewed 
inmates. 
 The 16 total themes could be more broadly grouped into those relating to 
adherence, non-adherence, or management (Appendix- Table 3). The theme 
Patient Education was the only theme identified across multiple questions; 
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appearing in Q1, Q3, and Q4. Education most commonly comes in the form of 
providing information about the specific medication, the patient's disease, 
medication or intervention adherence, and chronic disease to support therapy 
effectiveness28. Whether it be doctors, nurses, or other health care workers 
providing support to inmates- knowledge is passed from provider to patient and 
ultimately translates into adherence. This is important in that it provides evidence 
of the role clinicians play in supporting medication adherence as well as 
facilitating the management of an inmate-patients’ medication regimen.  
Patient education can be a tool for combating identified recurring causes of 
non-adherence such as Lack of Need, Lack of Faith, Personal Beliefs, and 
Unmatched Expectations. In any of these cases, the provider becomes 
instrumental in communicating the purpose of therapy to the patient while also 
dispelling any misinformation. The variety of ways to apply patient education 
stresses how provider intervention is essential to medication management and 
adherence of the inmate-patient. 
 Medication requests, in response to side effects or simply patient desire, and 
subsequent medication therapy management warrant additional discussion due to 
the impact on inmate-patient care. To start, changes to medication regimens in 
correctional health facilities mirror that of the free world. For example, a 
physician may increase a dose if a medication’s effects are not apparent, decrease 
the dose, switch to a therapeutic alternative, or the patient may request a change if 
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they are not experiencing the outcomes they desire. At times, inmate-patients 
would request a medication to help with sleep or anxiety, but often these 
medications are highly controlled or off limits in the prison and could not be 
prescribed. The majority of participants reported at least one self-requested 
alteration to their medication regimen, most commonly in response to side effects, 
which was almost always accommodated by the clinician. Antipsychotics were 
the medication class for which participants most frequently requested alterations, 
with justifications supported primarily by Q3. Side effects such as weight gain, 
extra-pyramidal symptoms (EPS), and dizziness contributed frequently as barriers 
to adherence. With a metabolic role, the weight gain, and potential for 
irreversibility, the EPS, close therapeutic monitoring is required by providers. 
Higher incidence of type 2 diabetes mellitus, cardiovascular disease, and life-long 
tardive dyskinesia (a subset of EPS) coinciding with antipsychotic therapy 
warrants transition to therapeutic alternatives to prevent patient morbidity29,30. 
Thus, it is expected that patients requiring antipsychotics will receive a greater 
degree of medication management during their time in prison. Aside from the 
antipsychotic medications, participants expressed minimal complaints about 
current side effects. Overall, inmate-patients on antipsychotic therapy in prison 
represent a high-risk population that require specialized attention from 
correctional health care providers.  
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 Of additional importance was the expression of Lack of Provider Access 
among interviewed inmate-patients. For those located in prison, a medication 
change could be obtained through writing a sick note or reporting their symptoms 
to a member of the health staff. This process could take substantial time, often 
two to four weeks, for the inmate's request to be triaged appropriately and for a 
session with a physician to become available. For medications requiring frequent 
side effect and efficacy monitoring, such as the antipsychotics, delays in seeing a 
care provider could negatively impact care. Thus, in both the prison and extended 
supervision populations, this theme was ultimately viewed as a barrier to 
medication adherence and routine care.  
Previously, for an inmate-patient in the halfway house, changing their regimen 
proved difficult as it required they receive all medical care back at the prison they 
originally came from. New regulations brought on by the Affordable Care Act 
(ACA) work to reduce this barrier to care by allowing halfway house residents to 
purchase private insurance or qualify for Medicaid and Medicare on release31,32. 
Inmate-patients can now utilize this insurance during their time in extended 
surveillance to improve their access to care in the community. Allowing inmates 
to access community-based health services directly while in the halfway house 
helps to establish the halfway house residents’ care team at an early stage, 
allowing them to adapt to their new settings, and potentially reduce provider 
burden in the correctional health care system. Involving insurance and other 
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regulatory bodies at an earlier stage in transition, may effectively address the 
expressed barrier of Limited Provider Access. Putting inmate-patients in a 
position to easily and regularly make use of their care team, with access to the 
educational support of their clinicians, will likely promote optimal adherence and 
allow for realization of the greatest benefits from therapy. 
 Previous research into inmate-patient perspectives on barriers or facilitators of 
adherence primarily focuses on the experiences of specific disease-states in the 
correctional setting. The majority of adherence research relates to inmate-patients 
with HIV/AIDS or psychiatric illnesses, with data lacking for chronic conditions 
such as hypertension and asthma. Interviews conducted with incarcerated women 
suffering from HIV identified factors such as increased knowledge of their 
disease, improving CD4 levels, privacy associated with “keep on person” 
medications, and the routine of prison life as factors enhancing medication 
adherence among others. Conversely, this same study found the stigma of 
receiving antiretroviral therapy for HIV and participating in the medication line as 
barriers to adherence33.  
Another study, analyzing factors associated with former inmate HIV patients' 
use of health care on release, found that major factors related to interpersonal 
relationships, professional relationships, coping strategies and resources, and 
individual attitudes affected health care utilization34. This study is similar to the 
current findings in the sense that "professional relationships" and "coping 
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strategies and resources" coincide with the receipt of Patient Education from 
correctional health care providers. For those receiving psychotropic medications, 
a review by Shelton et al. found that factors influencing medication adherence 
could be generally grouped into the following categories: prisoner demographic 
characteristics, prior use of psychotropic medication, prisoner insight into mental 
health treatment needs, prison environment, and medication side effects35. In a 
randomized controlled trial among female inmate-patients with bipolar disorder, 
authors found that inmate-patients skipping the greatest number of doses had the 
lowest levels of baseline adherence and most severe symptoms36. Conversely, 
they found that as adherence increases over time, each inmate reported symptoms 
decreased, considered a sign of therapy effectiveness. In this same study, mood 
stabilizers, such as lithium, were the most commonly skipped medication 
followed by antipsychotics36. In the current study, findings provide justification 
for skipping these medications as participants complained of Cognitive Side 
Effects, Therapy-limiting Side Effects, and Physical Side Effects when referring 
to lithium and antipsychotics. Since mood-stabilizers and antipsychotics are the 
main form of treatment for a variety of mood disorders, such as bipolar disorder 
and schizophrenia, addressing side effects and other associated barriers to 
adherence becomes increasingly important for the achievement of therapeutic 
goals. This study builds upon the themes identified previously in the literature and 
presents a diversity of other factors affecting inmate adherence. 
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Pharmacist Role 
A pharmacist has the capacity to serve in many roles due to their broad 
knowledge base and in-depth familiarity with medication use and distribution. 
Previous studies have proven the pharmacist's ability to directly monitor 
therapeutic levels, prevent and address side effects, provide education, and reduce 
costs in a variety of settings while striving to achieve optimal therapy goals14,28,37–
41. In general, pharmacists are currently employed by community pharmacies, 
hospitals, ambulatory care clinics, and a variety of outpatient settings. 
Pharmacists are also found in the correctional health system and have 
responsibilities ranging from verifying medications for administration to 
collaborative drug therapy agreements (CDTA) where they carry out 
comprehensive medication management for specific populations. Commonly 
managed disease-states include HIV, hepatitis, diabetes, and patients receiving 
anticoagulation42–44.  
Opportunities for specialization in correctional health care exist for pharmacy 
school graduates in the form of a pharmacy residency. Examples of programs 
currently offered in correctional health care include UConn Health’s Correctional 
Managed Health Care (CMHC) residency and University of Texas Medical 
Branch’s (UTMB) managed care pharmacy45,46. At the Federal level, the Bureau 
of Prisons (BOP) residency exists and offers training in mental health, ambulatory 
care, and diabetes management among other specialties43,47. With the 
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aforementioned opportunities in mind, the recent ASHP guidelines for 
pharmacists in correctional settings further cement the clinical benefits offered by 
the pharmacist22. The results of this study offer insight into how the pharmacist 
can further serve the correctional population while continuing to advance their 
role as a provider by delivering safe and efficacious care. Applications of the 
pharmacist’s skillset have been developed to achieve this end and are suggested in 
the following paragraphs.  
The two main functional areas identified for pharmacist intervention are the 
outpatient and inpatient segments of the care continuum, with the most substantial 
improvement possible in the inpatient setting. From an inpatient perspective, care 
delivered specifically within the prison medical department, it is clear that 
populations with chronic illnesses require continual medication management and 
the current availability of providers is limited. As previously mentioned, the side 
effect profile of antipsychotics requires close monitoring and frequently 
necessitates therapeutic alterations. Pharmacists are well equipped to address this 
medication monitoring need after receiving the Board Certified Psychiatric 
Pharmacist (BCPP) credential that exists through the Board of Pharmacy 
Specialties (BPS)48. For this certification, pharmacists are required to have 
practiced for from two to four years, based on residency experience, with a 
percentage of their time devoted to psychiatric pharmacy activities and must 
objectively demonstrate their knowledge by sitting for a board examination48. 
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CDTA’s for the psychiatric population exist in certain care settings, and should be 
further implemented to allow pharmacists to practice at the top of their license. 
The BPS also offers the Board Certified Pharmacotherapy Specialist (BCPS) 
credential49. With this, the pharmacist has demonstrated an in-depth knowledge of 
medications and can effectively provide comprehensive medication therapy 
management (MTM) for many different disease-states49.  
Under the care of a BCPS or BCPP certified pharmacist, each patient’s 
medication regimen could be optimized to reduce drug interactions, limit side 
effects, and titrated to achieve therapeutic goals. Employing pharmacists with 
either the BCPP or BCPS credential works to combat the provider shortage in 
prisons, resolving issues specific to this psychiatric population and other disease 
state, ultimately allowing the primary care physicians to focus their limited time 
on other aspects of patient care. In this way, another care provider would be made 
available to the correctional health system, impacting medication adherence 
through optimum medication management. As well, the pharmacist can help 
address inmate-patients that may be resistant to therapy through motivational 
interviewing. Combined with pharmacist's empathy, applying motivational 
interviewing to the incarcerated population could foster change that could 
improve adherence and extend to other aspects of the patient's life. 
 From an outpatient standpoint, the pharmacist has the potential to increase 
their functionality to released inmates by working within the existing health 
35 
infrastructure. For released inmates, there is often misinformation about how to 
reengage in health care on return to the community. Without this information, the 
inmate is at risk of failing to reestablish their care team which could contribute to 
non-adherence. Other factors affecting adherence for any patient in the 
community include costly medications, lack of care coordination, and personal 
factors such as patient health literacy and support networks4. Since inmates 
become responsible for all health care on release, it can be inferred than an extra 
form of support would help them with this transition. As stated earlier, the 
abundance of community pharmacies in the United States gives inmates an easy 
source of health information on release from prison. Pharmacists serve a broad 
population of patients in the community pharmacy, but may not be privy to the 
experience of those released from prison. Without knowledge of the transitions of 
care that occur between prison and the community, or extended surveillance and 
community, the pharmacist cannot serve inmate-patient’s post-incarceration to the 
best of their ability. Community support programs exist to help patients navigate 
during the high-risk transitionary period, but no relationship between these 
programs and community pharmacies currently exists. A synergistic solution 
would be for community pharmacies to establish contact with community health 
programs to facilitate post-incarcerated patients’ integration into the health 
system. As a regular member of interdisciplinary care teams, pharmacists have 
significant experience with interprofessional communication and exposure to a 
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diversity of care settings; allowing for effective communication to and from 
community health programs.  
Additionally, if the pharmacist were to have greater knowledge of the 
patient’s needs post-incarceration, they could direct patients to appropriate health 
services or, with knowledge of their transitional health coverage, suggest cheaper 
payment methods. An example of the former would consist of a post-incarcerated 
patient coming to the pharmacy without an established primary care physician, 
requesting more information. The latter could occur when the patient’s insurance 
coverage has not been instated on release from prison and needs medication. In 
this case, the pharmacist can utilize a prescription discount card, which are 
common in the community pharmacy, or offer recommendations for low cost 
over-the-counter (OTC) medications to help the patient save money. Through the 
community pharmacy, the pharmacist would be addressing transitional adherence, 
a critical step in the inmate-patient’s care process, in addition to the normal day-
to-day needs of released inmates. 
 To better prepare pharmacists, there should be a coordinated effort between 
the prison facility, government at local and state levels, community health 
programs, and community pharmacies as a whole. A potential solution would be 
the implementation of a certification program, recurring academic seminar, or 
Continuing Education credit that provides pharmacists with knowledge they need 
to manage this vulnerable population. While the pharmacist already services this 
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population in several ways, pharmacists have the potential to do much more from 
the inpatient and outpatient standpoints. Whether providing education and 
guidance to promote adherence in the community pharmacy, or directly managing 
medications in the correctional health setting, there are strides to be made for 
pharmacists in the realm of correctional health.  
Limitations 
While every effort was made to ensure the rigor of this study, several limitations 
were present that prevent complete realization of the true scope of inmate-patient 
perspectives on health care. The most significant limitation was the inability to 
obtain inmate-patients' Medication Administration Records (MAR) due to 
scheduling, travel, and administrative barriers. Using the MAR would have 
provided an objective source for evaluating the patient's overall adherence and 
could have served as a cross-reference to their self-reported answer. Using 
patients' self-reported adherence served as a less accurate marker but was 
ultimately the only available resource. While there is no perfect measure of 
adherence, the standard used is often proportion of days covered (PDC). For 
instance, the Pharmacy Quality Alliance (PQA) uses PDC as their standard 
measure of adherence when developing medication-use measures for medication 
safety and adherence26,27.The PDC is calculated by the total days of medication 
supply during a time interval divided by the total length of time in the interval 
period; yielding the percentage of days with medication available50 This 
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calculation is often made through evaluation of pharmacy claims data, by 
comparing the fill dates of the patient's medication27. A patient is often considered 
adherent when their PDC is 80% or more for a given period of time, and non-
adherent below this threshold51. To go along with the missing MAR data, this 
study did not use other objective forms of data collection such as surveys, scales, 
or questionnaires. Employing these methods would have allowed for greater data 
standardization, comparison among participants, and potentially the use of 
statistical analysis.  
 Second, the open-ended questions could be deemed ambiguous and open to 
interpretation by each interviewee. Additional probing may have elicited different 
responses from participants that may have varied between different interviews. 
Recruiting also presented as a major limitation for this study. By passively 
posting fliers in the prisons and halfway houses, inmates could have easily 
overlooked or forgotten to self-enroll in the study. The final cohort of 23 
participants yielded interesting themes, but further evidence could have been 
generated from a larger and more diverse group of participants. Among the 
patient population, there was an imbalance between adherent and non-adherent 
with the majority of participants reporting adherent. This imbalance may be 
explained by the recruiting method, as it could be inferred that the non-adherent 
population did not care enough to participate in the study since they already do 
not actively participate in their treatment. A more active approach, such as 
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planned informational sessions regarding the study and face-to-face enrollment, 
may have yielded a more balanced study population. As well, the interviewed 
population did not include female inmate-patients, so the study is restricted to 
purely the male's perspective of the correctional health setting. In terms of 
stratification of the interviewed population, the analysis primarily focused on the 
main diagnosis of the patient and was not segregated based on the type of 
medication. Again, the absence of MAR data prevented further stratification of 
the study participants. 
Future Research 
As stated, inmate medication adherence is understudied and is primarily focused 
in select disease-states such as HIV/AIDS and mental illnesses. However, even 
these disease states, are understudied and current research does not fully capture 
inmate-patient perspectives on medication adherence and experience with 
medication management. Thus, additional studies in a diversity of disease states 
using objective measures of adherence must be conducted to further evaluate 
factors affecting adherence in the correctional health setting. This study has 
identified themes surrounding inmate-patient perspectives on medication 
adherence and management. Building upon this, strategies for integrating 
pharmacists in the inpatient and outpatient settings may provide a means of 
addressing deficits in adherence at key junctures in the correctional care process 
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while efficaciously employing pharmacists' unique skillset for optimum 
medication therapy management.  
While the proposed roles for the pharmacist make theoretical sense, additional 
studies are necessary to gauge the value of direct pharmacist intervention on the 
adherence and subsequent health outcomes of inmate-patients. A potential study 
would be to compare inmate-patients supplied with intensive pharmacist 
medication management in the inpatient setting to a cohort with the facility’s 
current standard of care. Assessing measures such as adherence, well-being, cost 
of care, and quality of life would prove a means of evaluating pharmacists' impact 
in this role. In the outpatient setting, development of resources to educate 
community practitioners about the path of inmate-patients on reintegration to the 
community will serve as the next best step forward. Future studies should also 
capture inmate-patient perspectives specifically on the pharmacist and their roles 
in both the correctional setting and in the community. Utilization of the 
pharmacist’s services in these settings was not captured in the present study, but 
may offer additional clues in regards to how inmate-patients access care.  
 Additional studies are suggested to examine pharmacist involvement with the 
patient, but also with other providers in the correctional health setting. The theme 
Limited Provider Access demonstrated the frustration inmate-patients experienced 
when trying to utilize the health service in pursuit of medication inquiries or 
routine care. An expanded role for pharmacists should be explored, supported by 
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data regarding current provider time burden, illuminating value added supplied by 
the pharmacist. The prevalence of Patient Education throughout this study also 
calls for a greater assessment of the type of education most commonly provided to 
inmate-patients and the content most commonly requested. From an alternate 
perspective, the quality of the patient-provider relationship can be assessed in 
order to understand those essential factors that facilitate communication of 
medication education. At the end of the day, the patient is first and foremost in 
any health care setting. Studies to identify key factors of importance throughout 
inmate-patients' experience with correctional health care will provide evidence to 
better facilitate the implementation of patient-centered care in the correctional 
health setting. 
Conclusion 
Themes identified suggest the benefit of patient education in both the inpatient 
correctional health setting and outpatient on inmates’ transition to the community. 
From the inpatient setting, pharmacists are well suited to perform comprehensive 
medication therapy management for the psychiatric population and other chronic 
illnesses. In an outpatient setting, the community pharmacist is poised to supply 
medication and additional health information to inmates in transition. Interviews 
conducted during this study provided valuable new details regarding inmate-
patient perceptions of medication adherence and medication therapy management 
as a part of their treatment regimen. Overall, the pharmacist’s adept medication 
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knowledge and availability allow for in-depth medication management and 
support of inmates’ medication adherence. Further incorporation of the 
pharmacist into correctional health care will allow for increased patient-centered 
care and will likely bring about improvements in this population’s health. 
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Appendices 
 
Table 1. Projected Parent Study Enrollment 
Patient Groups Adherent Non-adherent 
Diabetes Male - 5        Female - 5 Male - 5        Female - 5 
Hypertension Male - 5        Female - 5 Male - 5        Female - 5 
HIV/AIDS Male - 5        Female - 5 Male - 5        Female - 5 
Schizophrenia Male - 5        Female - 5 Male - 5        Female - 5 
Bipolar Male - 5        Female - 5 Male - 5        Female - 5 
Depression Male - 5        Female - 5 Male - 5        Female - 5 
Substance Abuse Male - 5        Female - 5 Male - 5        Female - 5 
 
Table 1 Description: The projected enrollment for the “Inmate Self Care” study 
was 140 participants to ensure saturation among each of the specified groups of 
interest. Adherence or non-adherence was assigned based on review of the 
inmate-patients’ medication administration record (MAR) or, if MAR was 
unavailable, based on the patient's self-reported response based on their overall 
sense of adherence for the previous 3 months. 
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Table 2. Sub- study Sample Demographics 
 
Table 2 Description: The mental illness group contained primary diagnoses of 
depression, bipolar disorder, schizophrenia, and substance abuse. The physical 
illness group contained the diagnoses of hypertension, diabetes mellitus, and 
HIV/AIDS. Adherence status was based on patient self-report based for the 
previous 3 months. Halfway house or prison location was based on place when 
interviewed. For Education, college degree includes bachelors or associates; 
‘Other’ classification includes some college (1) or unassigned (1). For Ethnicity, 
the ‘Other’ classification represents unknown (1) and mixed race (3). 
Abbreviations: Dx=Diagnosis 
Demographics:  
Adherent  n=17 
% 
Non-adherent   n=6 
% 
Total   N=23 
% 
Gender:        
Male 17 6 23     
Location:    
Prison 5 2 7 
Halfway House 12 4 16     
Primary Dx:    
Hypertension 1 0 1 
Diabetes Mellitus 2 1 3 
HIV/AIDS 3 0 3 
Depression 4 3 7 
Bipolar Disorder 2 1 3 
Schizophrenia 2 1 3 
Substance Abuse 3 0 3     
Ethnicity:    
Black 8 1 9 
Hispanic 5 0 5 
White/Caucasian 2 3 5 
Other 2 2 4     
Education:    
College Degree 3 1 4 
High 
School/GED/Technical 5 5 10 
Some High School 7 0 7 
Other 2 0 2     
Family Support:    
Yes 13 3 16 
No 4 3 7 
45 
Figure 1. Theme Web 
 
 
Figure 1 Description: The web shows the themes identified when each question 
was asked. The red lines extending from each box signify the presence of the 
theme Patient Education among questions 1, 3, and 4.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Q1 Q2
Q3 Q4
Tangible Benefits
Potential Risks
Acute Relief
Counseling
Loss of Faith
Momentary Disruptions
Timeliness
Lack of Need
Personal Beliefs
Unmatched Expectations
Limited Provider Access
Data Use
Cognitive Side Effects
Therapy-limiting Side Effects
Physical Side Effects
Patient Education
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Table 3. Adherence, Non-adherence, Management Theme Classifications 
Adherence Non-adherence Management 
Acute Relief Cognitive Side Effects Cognitive Side Effects 
Counseling Lack of Need Data Use 
Potential Risks Lack of Provider Access Lack of Provider Access 
Patient Education Loss of Faith Physical Side Effects 
Tangible Benefits Momentary Disruptions Patient Education 
  Personal Beliefs Therapy-limiting Side Effects 
  Physical Side Effects Unmatched Expectations 
  Therapy-limiting Side Effects   
  Timeliness   
  Unmatched Expectations   
 
Table 3 Description: Thematic classification from Q1, Q2, Q3, Q4 could be 
separated based on the impact they had on either adherence or medication 
management. Themes were separated based on the context they were presented 
from the interview participant. The adherence designation suggests the theme 
promotes proper medication adherence, and non-adherence suggests the theme 
detracts from proper medication adherence. Management is a compilation of 
themes that are important for optimum medication therapy management. 
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